## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -3.5% below STRENGTH zone (4.0-10.0%); PEG 3.10 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($75.37)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Implied Volatility Surging for Colgate-Palmolive Stock Options**
- Source: TradingView | 20251205T170808 | Somewhat-Bearish | Relevance: 100%
- Investors in Colgate-Palmolive Company (CL) should note the surging implied volatility for its stock options, particularly the Dec. 19, 2025 $35 Call. This indicates market expectations of a significant price movement, possibly due to an upcoming event. Analysts currently have a negative outlook on Colgate-Palmolive, with a Zacks Rank #4 (Sell), suggesting this high implied volatility could be an opportunity for options traders to sell premium.

**2. Colgate-Palmolive (CL): Revisiting Valuation After This Year’s 14% Share Price Slide**
- Source: Simply Wall Street | 20251205T090844 | Somewhat-Bullish | Relevance: 100%
- Colgate-Palmolive (CL) has seen its share price fall by 14% this year, despite steady underlying business growth, prompting a reassessment of its valuation. The stock is currently trading at about $77.60, against a narrative fair value of $87.21, suggesting it might be undervalued. However, its P/E ratio is higher than the industry average, and potential risks like raw material costs and consumer caution could impact margin expansion.

**3. Colgate and PETA Science Group Team Up to Sponsor Scientists from India for Non-Animal Toxicity Test Training**
- Source: PETA | 20251205T154359 | Somewhat-Bullish | Relevance: 100%
- Colgate-Palmolive and PETA Science Consortium International e.V. have sponsored six scientists from India to undergo training in non-animal toxicity testing methods in the U.S. This initiative equips scientists with skills to replace animal use in chemical testing. The Science Consortium has now sponsored over 40 scientists for this program.

**4. First Trust Advisors LP Reduces Position in Colgate-Palmolive Company $CL**
- Source: MarketBeat | 20251205T090844 | Neutral | Relevance: 100%
- First Trust Advisors LP significantly reduced its stake in Colgate-Palmolive Company (NYSE:CL) by 11.2% in the second quarter, selling over 320,000 shares. Despite this, several other institutional investors increased their holdings in CL during the same period. The company also reported strong quarterly earnings, topping analyst estimates for EPS, and announced a quarterly dividend.

**5. Colgate-Palmolive (CL): Revisiting Valuation After This Year’s 14% Share Price Slide**
- Source: Simply Wall Street | 20251205T082538 | Somewhat-Bullish | Relevance: 100%
- Colgate-Palmolive (CL) has seen its share price quietly slip by 14% this year, despite steady underlying business growth, prompting a re-examination of its valuation. The stock closed at $77.60, implying an 11% undervaluation compared to a narrative-driven fair value of $87.21, based on anticipated margin expansion and reinvestment for growth. However, its current P/E ratio of 21.5x surpasses the household products average, indicating potential valuation risk if growth expectations are not met.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.07M) |
| Sells | 7 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.0% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.1x requires aggressive growth execution.
3. Long-term trend broken: trading 9.6% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.10 signals overvaluation risk, limited margin of safety. Forward P/E 20.3x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $64.4B |
| Beta | 0.29 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.10 |
| Forward P/E | 20.3 |
| Current P/E | 21.4 |
| YoY Growth | 5.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.5% to -3.5% (-4.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.5pp (needs >4.0% for momentum thesis). Below SMA200 (0.90x), long-term trend not supportive. RSI neutral at 46. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.48% (CS: 24) | Weak |
| RSI_14 | 46.4 | Neutral |
| MACD Histogram | -0.16 | Bearish |
| vs SMA20 | 0.988x | Below |
| vs SMA50 | 0.996x | Below |
| vs SMA200 | 0.904x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $78.07
- **Stop Loss:** $75.37 (3.5% risk)
- **Target:** $80.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 185
- **Position Value:** $14,442.95
- **Portfolio %:** 14.44%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*